small molecule microarrays (chemical genomics) for drug target screening

History:

Graffinity Pharmaceuticals merged with MyoContract in 2004 to become Santhera Pharmaceuticals.

Employment

Email:

Fax:

Mail:

General Info:

Ticker:

Employees:

Regions:
Europe

Research Focus:
Microarray/Chip Technologies

 

Profiles:

 

News:

Keywords: 

Strategic Partnerships: Aventis Pharma Celera Genomics Structural Genomix